

• **Name:**

James Chih-Hsin Yang

• **Current Position:**

Director and Distinguished Professor, Graduate Institute of Oncology, National Taiwan University

Director, Department of Oncology, National Taiwan University Hospital

• **Country:**

Taiwan (ROC)

• **Educational Background:**

PhD, Graduate Institute of Clinical Medicine

MD, School of Medicine, Medical College, National Taiwan University

• **Professional Experience:**

Staff physician, Department of Oncology, National Taiwan University Hospital

Clinical Associate, Medicine Branch, NCI, NIH, USA

Resident, Department of Internal Medicine, National Taiwan University Hospital

• **Professional Organizations:**

Board of Director, International Association for the study of Lung Cancer (IAS LC)

• **Main Scientific Publications:**

1. Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH. et al. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis Journal of Thoracic Oncology, 2019 (on line)
2. Yang JC, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A and Ahn MJ. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and leptomeningeal metastases: the BLOOM study Journal of Clinical Oncology (accepted).
3. Yang JC\*, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR-TKI therapy: CAURAL brief report Journal of Thoracic Oncology 2019;14(5):933-936
4. Yang JC\*, Shirish M, Gadgeel SM, Sequist L, Wu SL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos, Amita Patnaik A. Pembrolizumab in Combination With

- Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation. *Journal of Thoracic Oncology* 2019 March ;14(3):553-559 (\*Corresponding author)
5. Lee CK, Man J, Lord S, Cooper W, Links M, GebSKI V, Herbst RS, Gralla RJ, Mok T. and Yang JC. Clinical and molecular characteristics of survival benefit from second-line therapy with checkpoint inhibitors in advanced non-small cell lung carcinoma. *JAMA Oncology* 2018 Feb 1;4(2):210-216.
  6. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenzov YE, Ghiorghiu S, Stetson D, Markovets A, Barrett J, Thress KS, and Jänne PA. Osimertinib as First-Line Treatment for EGFR-Mutation-Positive Advanced Non-Small-Cell Lung Cancer. *Journal of Clinical Oncology* 2018 Mar 20;36(9):841-849.
  7. Yang JC\*, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in pre-treated T790M positive advanced NSCLC: AURA study Phase II extension cohort. *Journal of Clinical Oncology* 2017 Apr 20;35(12):1288-1296
  8. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL, Clinical Activity of Afatinib in Advanced NSCLC Harboring Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: Combined Analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. *Lancet Oncology* 2015 July;16(7): 830-838
  9. Yang JC\*, Wu YL\*, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V and Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials *Lancet Oncology* 2015 Feb;16(2):141-51.
  10. Janne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam S, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, EFelip E, Kim JH, Frewer P, Cantarini M, Brown K, Dickson P, Ghiorghiu S and Ranson M. AZD9291 in EGFR TKI resistant nonsmall cell lung cancer. *New England Journal of Medicine* 2015 Apr 30;372:1689-1699
  11. Mok T, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *New Engl J Med*. 2009 Sep 3; 361(10):947-57